July 26, 2017 The MPN Research Foundation is proud to announce the five winners of its 2017 Challenge Grant program. This is a combined effort with the Leukemia & Lymphoma Society. The projects selected were vetted by a review committee of MPN scientists including MPNRF’s Scientific Advisory Board. They reflect the priorities of the Foundation… Read More »MEET THE 2017 MPN CHALLENGE GRANT WINNERS
A MPN Landmark Survey funded by Incyte Corporation has been published! Key information from the MPN LANDMARK SURVEY is now available for review and sharing. It includes a summary of the findings and some interviews with the MPN LANDMARK SURVEY steering committee members. The patient-friendly summary includes separate surveys of patients and physicians about MF, PV,… Read More »MPN LANDMARK SURVEY
ASU and the Mayo Clinic are seeking MPN cancer patients, ages 18 and up to participate in a research study. The purpose of the research is to determine the feasibility and preliminary effects of a mobile application-based health intervention on symptom burden (i.e., pain, fatigue, depression, anxiety, and sleep) and quality of life in Myeloproliferative… Read More »ASU AND MAYO CLINIC SEEK PARTICIPANTS FOR MOBILE APP SYMPTOM TRACKING
This week the FDA approved a novel and exciting curative therapy for Acute Lymphoblastic Leukemia. The drug company Novartis’ Kymriah, also known as tisagenlecleucel, is what is known as Chimeric Antigen Receptor Therapy, or CAR-T, in which a patient’s own cells are extracted, re-engineered as cancer-fighting mini-machines and re-introduced to the patient. Results were demonstrated in a… Read More »WHAT DOES THE APPROVAL OF KYMRIAH MEAN FOR MPN PATIENTS?
In a few days, the month will change to September, which is recognized nationally as Blood Cancer Awareness Month. While you are already aware of MPNs, or myeloproliferative neoplasms, there are many factors indirectly but adversely affecting people living with Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. A few we hear from patients frequently are: Friends or family… Read More »WHAT DOES AN AWARENESS CAMPAIGN HAVE TO DO WITH PV, ET AND MF?
April 11, 2018Chicago, IL and Australia The MPN (Myeloproliferative Neoplasms) Research Foundation (MPNRF) and MPN Alliance Australia (MPN AA) are proud to announce a research partnership focused on the MPN Interferon Initiative. MPNRF and MPN AA are both patient advocacy organizations who work on behalf of patients with myeloproliferative neoplasms, a group of rare, chronic… Read More »MPN ALLIANCE AUSTRALIA AND MPN RESEARCH FOUNDATION PARTNER TO SUPPORT RESEARCH
MPN Research Foundation is excited to have sponsored the creation of the NCCN (National Cancer Center Network) MPN patient guidelines. To follow up on this publication, which helps inform patients about best-practices in care for MPNs, the NCCN is hosting a free live webinar focusing on myeloproliferative neoplasms (MPN) especially for patients and their family… Read More »NCCN TO HOST WEBINAR FOR MPN PATIENT GUIDELINES
On March 31st, 2018 roughly 100 hematologists/oncologists and MPN experts from Asia, as well as Europe and the United States, came together at the 3rd annual MPN Asia event to present and discuss recent updates and scientific advancements of Myeloproliferative Neoplasms. A few key takeaways from the event came from the Ropeginterferon vs Hydroxyurea trial. This… Read More »After a 2-year study, ropeginterferon proves more effective than hydroxyurea
Your copy of the Spring 2019 Newsletter from the MPN Research Foundation is now available. You can click here to read it but if you would like a printed copy, please let us know by emailing Lexi Moore at lmoore@mpnrf.org. Filled with the latest news from the global MPN community, the newsletter includes information about MPNRF’s exciting 2019… Read More »MPNRF’S SPRING 2019 NEWSLETTER HAS ARRIVED!
